Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $5,100 | 5 | 88.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $400.00 | 1 | 7.0% |
| Education | $238.65 | 4 | 4.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Bayer HealthCare Pharmaceuticals Inc. | $1,900 | 2 | $0 (2021) |
| PFIZER INC. | $1,715 | 2 | $0 (2020) |
| GlaxoSmithKline, LLC. | $975.00 | 1 | $0 (2021) |
| Daiichi Sankyo Inc. | $525.00 | 1 | $0 (2024) |
| GENZYME CORPORATION | $400.00 | 1 | $0 (2017) |
| Lilly USA, LLC | $92.82 | 1 | $0 (2021) |
| Janssen Biotech, Inc. | $90.00 | 1 | $0 (2024) |
| Exelixis Inc. | $41.20 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $615.00 | 2 | Daiichi Sankyo Inc. ($525.00) |
| 2021 | $2,068 | 3 | Bayer HealthCare Pharmaceuticals Inc. ($1,000) |
| 2020 | $2,600 | 2 | PFIZER INC. ($1,700) |
| 2019 | $14.63 | 1 | PFIZER INC. ($14.63) |
| 2018 | $41.20 | 1 | Exelixis Inc. ($41.20) |
| 2017 | $400.00 | 1 | GENZYME CORPORATION ($400.00) |
All Payment Transactions
10 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/02/2024 | Daiichi Sankyo Inc. | ENHERTU (Drug) | Consulting Fee | Cash or cash equivalent | $525.00 | General |
| Category: ONCOLOGY | ||||||
| 05/30/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Education | In-kind items and services | $90.00 | General |
| Category: Oncology | ||||||
| 08/24/2021 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $975.00 | General |
| 04/22/2021 | Bayer HealthCare Pharmaceuticals Inc. | Vitrakvi (Drug) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Oncology | ||||||
| 04/15/2021 | Lilly USA, LLC | CYRAMZA (Drug) | Education | In-kind items and services | $92.82 | General |
| Category: Oncology | ||||||
| 09/30/2020 | Bayer HealthCare Pharmaceuticals Inc. | Stivarga (Drug) | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| Category: Oncology | ||||||
| 03/23/2020 | PFIZER INC. | — | Consulting Fee | Cash or cash equivalent | $1,700.00 | General |
| 05/29/2019 | PFIZER INC. | XTANDI (Drug) | Education | In-kind items and services | $14.63 | General |
| Category: ONCOLOGY | ||||||
| 10/02/2018 | Exelixis Inc. | — | Education | In-kind items and services | $41.20 | General |
| 04/10/2017 | GENZYME CORPORATION | JEVTANA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $400.00 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 2 | 55 | 82 | $10,237 | $4,715 |
| 2022 | 3 | 67 | 123 | $16,332 | $8,330 |
| 2021 | 4 | 144 | 252 | $43,834 | $20,071 |
| 2020 | 5 | 228 | 390 | $55,843 | $21,360 |
All Medicare Procedures & Services
14 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 27 | 51 | $7,495 | $3,528 | 47.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 28 | 31 | $2,742 | $1,188 | 43.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 27 | 60 | $7,980 | $4,111 | 51.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 13 | 24 | $5,544 | $2,395 | 43.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 27 | 39 | $2,808 | $1,824 | 64.9% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 37 | 89 | $21,296 | $9,467 | 44.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 52 | 99 | $14,713 | $6,777 | 46.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 44 | 53 | $3,964 | $2,387 | 60.2% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 11 | 11 | $3,861 | $1,439 | 37.3% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 63 | 175 | $24,328 | $10,064 | 41.4% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 32 | 52 | $11,654 | $4,233 | 36.3% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 87 | 115 | $8,300 | $3,771 | 45.4% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 18 | 18 | $6,671 | $2,139 | 32.1% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Facility | 2020 | 28 | 30 | $4,890 | $1,154 | 23.6% |
About Dr. Philip Brooks, MD
Dr. Philip Brooks, MD is a Hematology & Oncology healthcare provider based in Brewer, Maine. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2006. The National Provider Identifier (NPI) number assigned to this provider is 1942254818.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Philip Brooks, MD has received a total of $5,739 in payments from pharmaceutical and medical device companies, with $615.00 received in 2024. These payments were reported across 10 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($5,100).
As a Medicare-enrolled provider, Brooks has provided services to 494 Medicare beneficiaries, totaling 847 services with total Medicare billing of $54,476. Data is available for 4 years (2020–2023), covering 14 distinct procedure/service records.
Practice Information
- Specialty Hematology & Oncology
- Location Brewer, ME
- Active Since 05/22/2006
- Last Updated 12/20/2011
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1942254818
Products in Payments
- Vitrakvi (Drug) $1,000
- Stivarga (Drug) $900.00
- ENHERTU (Drug) $525.00
- JEVTANA (Drug) $400.00
- CYRAMZA (Drug) $92.82
- ERLEADA (Drug) $90.00
- XTANDI (Drug) $14.63
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Brewer
Shruti Bhandari, M.d, M.D
Hematology & Oncology — Payments: $4,837
Yelena Patsiornik, Md, MD
Hematology & Oncology — Payments: $1,999
Thomas Openshaw, Md, MD
Hematology & Oncology — Payments: $1,310
Dr. Sigrid Berg, Md, MD
Hematology & Oncology — Payments: $221.02
Jens Rueter, Md, MD
Hematology & Oncology — Payments: $218.42
Audrey Garrett, Md, MD
Hematology & Oncology — Payments: $173.66